Squamous, large cell, and adenocarcinoma, collectively termed non-small cell lung cancer (NSCLC), are diagnosed in approximately 75% of patients with lung cancer in the United States. The treatment of these three tumor cell types is approached in virtually identical fashion because, in contrast ...
Treatment of advanced non-small cell lung cancernon-small cell lung canceradvanced diseaseplatinum-based chemotherapydocetaxelpemetrexedEGFR inhibitorsPS 2 patientspharmacogenomicsIn the last decade the treatment of advanced-metastatic non-small cell lung cancer has substantially improved. If in the early ...
Non-small cell lung cancer (NSCLC) is a prevalent form of lung cancer. Patients with advanced NSCLC are currently being treated with various therapies, including traditional radiotherapy, chemotherapy, molecular targeted therapies and immunotherapy. However, a considerable proportion of advance patients wh...
Non-small-cell lung cancer is the most common type of lung cancer. It's serious, but treatment can sometimes cure it or stop it from getting worse. WebMD explains.
Comparison of the effectiveness of erlotinib, gefitinib, and afatinib for treatment of nonsmall cell lung cancer in patients with common and rare EGFR gene... Epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) are routinely used to treat non-small cell lung cancer (NSCLC) in...
The treatment results of 197 consecutive patients with non-small cell carcinoma of the lung managed at David Grant USAF Medical Center between January 1978 and September 1985 were reviewed. Patients were staged according to 1983 AJCC criteria as follows: 52 stage I, 28 stage II, and 117 stage...
Non-small cell lung cancer (NSCLC) is a heterogeneous disease characterized by a broad spectrum of oncogenic driver alterations. Currently, targeted therapies are the standard treatment for most oncogene-driven patients [1]. However, not all oncogenic drivers, such as human epidermal growth factor ...
Toward personalized treatment approaches for non-small-cell lung cancer Article 12 August 2021 Population based study on the progress in survival of primarily metastatic lung cancer patients in Germany Article Open access 11 July 2024 The current treatment landscape in the UK for stage III NSCL...
The FDA has approved pembrolizumab, a PD-1 immunotherapy drug, as first-line treatment for non-small cell lung cancer. FDA approves immunotherapy as first-line NSCLC treatment Wow, wow, wow! These are the kind of stories I need to hear to know I can manage and live with this disease. ...